Literature DB >> 26428847

Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma.

Liyun Xu1, Yanyan Huang1, Linlin Tan1, Wei Yu1, Dongdong Chen1, ChangChang Lu1, Jianying He1, Guoqing Wu2, Xiaoguang Liu3, Yongkui Zhang4.   

Abstract

T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) has been shown to play an important role in mediating NK-cell function in human diseases. However, the relationship between Tim-3 expression in natural killer (NK) cells and human lung adenocarcinoma remains unclear. We therefore investigated the expression of Tim-3 in NK cells and explored the effect of Tim-3 blockade on NK cell-mediated activity in human lung adenocarcinoma. Upregulated expression of Tim-3 on CD3-CD56+ cells (P<0.05) and CD3-CD56(dim) cells (P<0.05) of patients with lung adenocarcinoma was detected by flow cytometry. Moreover, Tim-3 expression in CD3-CD56+ NK cells was higher in patients with lung adenocarcinoma with lymph node metastasis (LNM) (P<0.05) or with tumor stage T3-T4 (P<0.05). Tim-3 expression in CD56(dim) NK-cell subset was higher in patients with tumor size ≥3cm (P<0.05), or LNM (P<0.05) or with tumor stage T3-T4 (P<0.05). Further analysis showed that higher expressions of Tim-3 on both CD3-CD56+ NK cells and CD56(dim) NK-cell subset were independently correlated with shorter overall survival of patients with lung adenocarcinoma (log-rank test, P=0.0418, 0.0406, respectively). Importantly, blockade of Tim-3 signaling with anti-Tim-3 antibodies resulted in the increased cytotoxicity and IFN-γ production of peripheral NK cells from patients with lung adenocarcinoma. Our data indicate that Tim-3 expression in NK cells can function as a prognostic biomarker in human lung adenocarcinoma and support that Tim-3 could be a new target for an immunotherapeutic strategy.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cytotoxicity; Human lung adenocarcinoma; Natural killer cells; T cell immunoglobulin- and mucin-domain-containing molecule-3

Mesh:

Substances:

Year:  2015        PMID: 26428847     DOI: 10.1016/j.intimp.2015.09.017

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  69 in total

Review 1.  New advances in immunotherapy for non-small cell lung cancer.

Authors:  Haifeng Qin; Fang Wang; Hui Liu; Zhen Zeng; Shasha Wang; Xin Pan; Hongjun Gao
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

Review 2.  Strategies to enhance NK cell function for the treatment of tumors and infections.

Authors:  Jacquelyn Freund-Brown; Leilani Chirino; Taku Kambayashi
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

3.  Circulating NKp46+ Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer.

Authors:  Emilie Picard; Yann Godet; Caroline Laheurte; Magalie Dosset; Jeanne Galaine; Laurent Beziaud; Romain Loyon; Laura Boullerot; Elodie Lauret Marie Joseph; Laurie Spehner; Marion Jacquin; Guillaume Eberst; Béatrice Gaugler; Françoise Le Pimpec-Barthes; Elizabeth Fabre; Virginie Westeel; Anne Caignard; Christophe Borg; Olivier Adotévi
Journal:  Oncoimmunology       Date:  2018-10-19       Impact factor: 8.110

4.  Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.

Authors:  Guanzhang Li; Zheng Wang; Chuanbao Zhang; Xing Liu; Jinquan Cai; Zhiliang Wang; Huimin Hu; Fan Wu; Zhaoshi Bao; Yanwei Liu; Liang Zhao; Tingyu Liang; Fan Yang; Ruoyu Huang; Wei Zhang; Tao Jiang
Journal:  Oncoimmunology       Date:  2017-07-28       Impact factor: 8.110

Review 5.  Killers 2.0: NK cell therapies at the forefront of cancer control.

Authors:  Jonathan J Hodgins; Sarwat T Khan; Maria M Park; Rebecca C Auer; Michele Ardolino
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

Review 6.  Role of natural killer cells in lung cancer.

Authors:  Ozge Nur Aktaş; Ayşe Bilge Öztürk; Baran Erman; Suat Erus; Serhan Tanju; Şükrü Dilege
Journal:  J Cancer Res Clin Oncol       Date:  2018-04-03       Impact factor: 4.553

Review 7.  Exploring the NK cell platform for cancer immunotherapy.

Authors:  Jacob A Myers; Jeffrey S Miller
Journal:  Nat Rev Clin Oncol       Date:  2020-09-15       Impact factor: 66.675

8.  PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients.

Authors:  Fernando Concha-Benavente; Benjamin Kansy; Jessica Moskovitz; Jennifer Moy; Uma Chandran; Robert L Ferris
Journal:  Cancer Immunol Res       Date:  2018-10-03       Impact factor: 11.151

Review 9.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 10.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.